Cabozantinib versus everolimus in advanced renal-cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Pyridines
  • Sirolimus

abstract

  • Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5024539

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1510016

PubMed ID

  • 26406150

Additional Document Info

start page

  • 1814

end page

  • 23

volume

  • 373

number

  • 19